These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32295157)

  • 21. An update on the role of daratumumab in the treatment of multiple myeloma.
    Costello C
    Ther Adv Hematol; 2017 Jan; 8(1):28-37. PubMed ID: 28042457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Study on Free Light Chain Assay and Serum Immunofixation Electrophoresis for the Diagnosis of Monoclonal Gammopathies.
    Kuriakose E; Narayanan Unni Cheppayil S; Kuzhikandathil Narayanan S; Vasudevan A
    Indian J Clin Biochem; 2019 Jan; 34(1):76-81. PubMed ID: 30728676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
    Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
    J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis.
    Turner KA; Frinack JL; Ettore MW; Tate JR; Graziani MS; Jacobs JFM; Booth RA; McCudden CR; Keren DF; Delgado JC; Zemtsovskaja G; Fullinfaw RO; Caldini A; de Malmanche T; Katakouzinos K; Burke M; Palladini G; Altinier S; Zaninotto M; Righetti G; Melki MT; Bell S; Willrich MAV
    Clin Chem Lab Med; 2020 Mar; 58(4):533-546. PubMed ID: 31940284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.
    Chapuy CI; Aguad MD; Nicholson RT; AuBuchon JP; Cohn CS; Delaney M; Fung MK; Unger M; Doshi P; Murphy MF; Dumont LJ; Kaufman RM;
    Transfusion; 2016 Dec; 56(12):2964-2972. PubMed ID: 27600566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.
    Kirchhoff DC; Murata K; Thoren KL
    J Appl Lab Med; 2021 Nov; 6(6):1476-1483. PubMed ID: 34293131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
    Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
    J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
    Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
    [No Abstract]   [Full Text] [Related]  

  • 29. False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
    Liang S; Feng W; Ma H; Zhang L; Jia C
    Hematology; 2022 Dec; 27(1):332-336. PubMed ID: 35255237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
    Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW
    MAbs; 2015; 7(2):311-21. PubMed ID: 25760767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential role of daratumumab in the treatment of multiple myeloma.
    Khagi Y; Mark TM
    Onco Targets Ther; 2014; 7():1095-100. PubMed ID: 24971019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.
    Roccatello D; Fenoglio R; Naretto C; Baldovino S; Sciascia S; Ferro M; Rossi D
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolving Role of Daratumumab: From Backbencher to Frontline Agent.
    Jain A; Ramasamy K
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):572-587. PubMed ID: 32331971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
    Slavcev M; Spinelli A; Absalon E; Masterson T; Heuck C; Lam A; De Cock E
    Clinicoecon Outcomes Res; 2021; 13():465-473. PubMed ID: 34135605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab: Beyond Multiple Myeloma.
    Ejaz K; Roback JD; Stowell SR; Sullivan HC
    Transfus Med Rev; 2021 Jul; 35(3):36-43. PubMed ID: 34312046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
    Usmani SZ; Mateos MV; Hungria V; Iida S; Bahlis NJ; Nahi H; Magen H; Cavo M; Hulin C; White D; De Stefano V; Fastenau J; Slavcev M; Heuck C; Qin X; Pei H; Masterson T; Lantz K; Gries KS
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):619-631. PubMed ID: 32852632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing.
    Tremblay T; Branch DR; Loubaki L
    Transfusion; 2020 Sep; 60(9):2090-2096. PubMed ID: 32632934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing.
    Chinoca Ziza KN; Paiva TA; Mota SR; Dezan MR; Schmidt LC; Brunetta DM; Ricci G; Basques FV; Barroso-Duarte F; Rocha V; Mendrone-Junior A; Dinardo CL
    Transfusion; 2019 May; 59(5):1827-1835. PubMed ID: 30779172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of Daratumumab on transfusion service costs.
    Cushing MM; DeSimone RA; Goel R; Hsu YS; Parra P; Racine-Brzostek SE; Degtyaryova D; Lo DT; Morrison M; Crowley KM; Rossi A; Vasovic LV
    Transfusion; 2019 Apr; 59(4):1252-1258. PubMed ID: 30620407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
    Murata K; McCash SI; Carroll B; Lesokhin AM; Hassoun H; Lendvai N; Korde NS; Mailankody S; Landau HJ; Koehne G; Chung DJ; Giralt SA; Ramanathan LV; Landgren O
    Clin Biochem; 2018 Jan; 51():66-71. PubMed ID: 27664535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.